Global database oversight committee - TGDOC

The TREAT-NMD Global Database Oversight Committee (TGDOC) is composed of representatives of the TREAT-NMD network plus representatives of patient organisations and each national registry. The Chair of the committee is Dr Hugh Dawkins and the Chair-elect is Dr Nathalie Goemans.

The TGDOC is responsible for reviewing all requests for data from the global database. This is intended to be a streamlined and rapid procedure in order not to delay approval. Requests will be responded to within a set time period of two weeks.

A list of all committee members is provided below, together with their disclosure statements.

Explanatory note: Examples of financial interest/arrangements to be disclosed include employment, grant support, honoraria, equity, ownership and royalties from a commercial organization within the last 3 years (after 01-01-2009) and valued at more than 2,000 Euro.


Nathalie Goemans Nathalie Goemans - Chair of TGDOC

M.D - UZ Leuven

Dr Nathalie Goemans (M.D. PhD) is a paediatrician and child neurologist, with certification in rehabilitation medicine and is currently head of the Neuromuscular Reference Centre within the department of Paediatrics and Child Neurology at  the University Hospitals Leuven, Belgium, and consultant in neuropediatrics at DVC St Jozef Antwerp, Belgium, a rehabilitation centre with residential setting for neuromuscular patients.

More Info


Craig Campbell Craig Campbell - Vice Chair - TGDOC

Pediatric Neurologist - London Health Sciences Centre

Dr Campbell practices at the Children’s Hospital-London Health Sciences Centre and at the University of Western Ontario, where he is an Associate Professor of Pediatrics, Clinical Neurology, and Epidemiology and Biostatistics. He is currently the medical director of the Pediatric Neuromuscular Clinic and the Pediatric Neurophysiology Laboratory.

More Info


Hugh Dawkins Hugh Dawkins - Outgoung Chair of TGDOC

Office of Population Health Genomics, Public Health Division, Department of Health
Curator of Australian National DMD Registry

Professor Dawkins leads the OPHG in the development and management of policies, plans and statewide services to minimise the impact of rare diseases. He provides advice and recommendations on issues relating to genetic testing, screening, gene patents, genetic privacy, stem cell therapy and the translation of new knowledge and technologies to improve in health services.

More Info

12 Apr 2017